Kynmobi
Drug Cns
NDC 63402-115-30
General payments
$658,445
Research payments
$0
Through program year 2023, $658,445 in general payments and $0 in research payments were reported against Kynmobi (Cns).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $169 | 8 |
| 2022 | General | $49,763 | 3,303 |
| 2021 | General | $306,195 | 10,652 |
| 2020 | General | $302,318 | 2,244 |
Breakdown
The top 5 of 8 recipients; each share is of general payments naming this product in 2023.
Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2023 where a state was reported.
Records
16,207 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.